Compare STC & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STC | NKTR |
|---|---|---|
| Founded | 1893 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 1994 | 1996 |
| Metric | STC | NKTR |
|---|---|---|
| Price | $68.65 | $73.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $81.00 | ★ $146.67 |
| AVG Volume (30 Days) | 205.9K | ★ 601.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $2,921,636,000.00 | $307,711,000.00 |
| Revenue This Year | $13.62 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $39.15 | ★ N/A |
| Revenue Growth | 17.32 | ★ 86.00 |
| 52 Week Low | $57.11 | $26.45 |
| 52 Week High | $78.61 | $109.00 |
| Indicator | STC | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 61.38 |
| Support Level | $65.34 | $64.28 |
| Resistance Level | $68.50 | $78.81 |
| Average True Range (ATR) | 1.29 | 2.61 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 68.55 | 90.85 |
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments: Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.